Scarica l'app Stockscreener
0.8313
2.30%
-0.0196
Dopo l'orario di chiusura:
.82
-0.0113
-1.36%
Precedente Chiudi:
$0.8509
Aprire:
$0.8366
Volume 24 ore:
109.04K
Relative Volume:
0.04
Capitalizzazione di mercato:
$56.32M
Reddito:
-
Utile/perdita netta:
$-46.12M
Rapporto P/E:
-0.9619
EPS:
-0.8642
Flusso di cassa netto:
$-41.02M
1 W Prestazione:
+0.71%
1M Prestazione:
-18.50%
6M Prestazione:
-0.20%
1 anno Prestazione:
-67.65%
Intervallo 1D:
$0.8215
$0.8455
Intervallo di 1 settimana:
$0.814
$0.90
Portata 52W:
$0.7113
$2.77
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.8313 | 57.65M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx N V Borsa (IFRX) Ultime notizie
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Treasury Yields: Is InflaRx NV forming bullish engulfing patternsEarnings Risk Summary & Smart Investment Allocation Tips - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus PT from Analysts - Defense World
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation - Sahm
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
InflaRx launches public offering of shares and warrants - MSN
InflaRx (NASDAQ:IFRX) Trading 10.4% HigherStill a Buy? - MarketBeat
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Yahoo Finance
History Review: Is InflaRx NV showing insider buyingWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Tech Rally: Can InflaRx NV sustain earnings growth2025 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
InflaRx Announces Participation in February Investor Conferences - marketscreener.com
Can InflaRx N.V. deliver consistent dividendsTrade Risk Summary & Weekly Market Pulse Alerts - mfd.ru
InflaRx NV Explodes After FDA Greenlight: Is IFRX the Biotech Underdog You’re Sleeping On? - AD HOC NEWS
Buyback Watch: Is InflaRx NV showing insider buyingJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Can InflaRx N.V. (IF0) stock sustain margin levelsMarket Performance Recap & Technical Analysis for Trade Confirmation - bollywoodhelpline.com
Is InflaRx N.V. stock positioned for digital transformationMarket Movers & Safe Entry Point Identification - bollywoodhelpline.com
Meme Stocks: Can InflaRx NV deliver consistent dividends2025 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours - Intellectia AI
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder - Sahm
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
InflaRx (IFRX) stock: biotech battleground after a volatile quarter and shifting expectations - AD HOC NEWS
InflaRx NV Is Exploding: Hidden Biotech Underdog or Just Another Hype Trap? - AD HOC NEWS
Raymond James reiterates Outperform rating on Inflarx stock at $9 target - Investing.com
Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 26.7% - MarketBeat
InflaRx reports potential efficacy signals in failed PG drug trial By Investing.com - Investing.com Nigeria
InflaRx (IFRX) Shares Mixed Results from Vilobelimab Phase 3 Trial in Ulcerative PG - parameter.io
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt - MSN
Momentum Shift: Is InflaRx NV stock a top pick in earnings seasonLong Setup & Growth-Oriented Investment Plans - Bộ Nội Vụ
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
InflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum - Nasdaq
InflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market - Nasdaq
InflaRx reports potential efficacy signals in failed PG drug trial - Investing.com
InflaRx N.V. Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - marketscreener.com
Inflarx N V Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):